Report cover image

Amyotrophic Lateral Sclerosis (ALS) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type (Sporadic ALS (SALS), Familial ALS (FALS)); By Treatment (Medication, Physical Therapy, Respiratory Therapy, Speech The

Publisher BlueWeave Consulting
Published Aug 01, 2024
Length 400 Pages
SKU # BLWC19215194

Description

Amyotrophic Lateral Sclerosis (ALS) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type (Sporadic ALS (SALS), Familial ALS (FALS)); By Treatment (Medication, Physical Therapy, Respiratory Therapy, Speech Therapy); By End User (Specialty Centers, Research & Academic Institutes); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))


Global Amayotrophic Lateral Sclerosis (ALS) Market Size to Expand at Significant CAGR to Surpass USD 1.45 Billion by 2030
Global Amayotrophic Lateral Sclerosis (ALS) Market is thriving due to rising ALS prevalence, increased awareness, advancements in therapeutic options, and government funding in enhancing research and development efforts for more effective treatments.
BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Amayotrophic Lateral Sclerosis (ALS) Market size to expand at a CAGR of 7.10% reaching a value of USD 1,456 million in 2030. Global Amyotrophic Lateral Sclerosis (ALS) Market is driven by increasing incidence rates, advancements in medical research, and rising awareness about ALS. Enhanced diagnostic techniques and growing investment in biotechnology for ALS treatment contribute significantly. Additionally, governments’ support and initiatives for rare disease research, along with collaborations between pharmaceutical companies and research institutions, propel market growth. The development of novel therapies and increasing clinical trials for ALS treatments further boost the growth of Global Amayotrophic Lateral Sclerosis (ALS) Market.
Opportunity – R&D initiatives for novel therapies
The growth of Global Amyotrophic Lateral Sclerosis (ALS) Market is significantly driven by increased research and development initiatives aimed at discovering novel therapies. Pharmaceutical companies and research institutions are investing heavily in R&D to develop innovative treatments, such as gene therapies, stem cell therapies, and novel drug candidates. These advancements are expected to improve patient outcomes and provide more effective treatment options, fueling market growth and offering hope for better management of ALS.

Impact of Escalating Geopolitical Tensions on Global Amayotrophic Lateral Sclerosis (ALS) Market
Escalating geopolitical tensions can significantly impact the Global Amyotrophic Lateral Sclerosis (ALS) Market. Disruptions in international trade and supply chains may lead to delays in the production and distribution of ALS medications and therapies. Increased regulatory scrutiny and trade restrictions can affect the availability of essential drugs and medical devices. Additionally, funding for ALS research may be diverted to address immediate geopolitical concerns, slowing advancements in treatment options. Fluctuations in currency exchange rates and economic instability can increase costs for healthcare providers and patients. Overall, geopolitical instability can hinder the accessibility and development of effective ALS treatments, impacting patient care and market growth.
Specialty Centers Are Major End Users of ALS Therapies
Global Amyotrophic Lateral Sclerosis (ALS) Market is comprised of specialty centers and research & academic institutes as end users. The specialty centers segment is a higher contributor to the growth of Global Amyotrophic Lateral Sclerosis (ALS) Market by end user. The segment dominates due to the specialized care and advanced treatment options provided by these centers, which cater specifically to ALS patients. These facilities offer comprehensive services, including diagnostics, multidisciplinary care, and access to clinical trials, making them the preferred choice for patients and driving their prominence in the market.
Competitive Landscape
Global Amayotrophic Lateral Sclerosis (ALS) Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd, BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Amayotrophic Lateral Sclerosis (ALS) Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Amayotrophic Lateral Sclerosis (ALS) Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Amayotrophic Lateral Sclerosis (ALS) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

400 Pages
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Amyotrophic Lateral Sclerosis (ALS) Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing prevalence of ALS globally
3.2.1.2. Advances in medical research and technology for ALS treatment
3.2.1.3. Growing healthcare expenditure and awareness
3.2.1.4. Rising geriatric population susceptible to neurological disorders
3.2.2. Restraints
3.2.2.1. High cost of ALS treatment options
3.2.2.2. Limited effectiveness of current therapies
3.2.2.3. Stringent regulatory requirements for drug approval
3.2.3. Opportunities
3.2.3.1. Research and development initiatives for novel therapies
3.2.3.2. Collaborations between pharmaceutical companies and research institutions
3.2.3.3. Technological advancements in diagnostic tools for early detection
3.2.4. Challenges
3.2.4.1. Ethical concerns related to experimental ALS therapies
3.2.4.2. Uneven access to ALS treatments across different regions
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Amyotrophic Lateral Sclerosis (ALS) Market: Marketing Strategies
5. Global Amyotrophic Lateral Sclerosis (ALS) Market: Pricing Analysis
6. Global Amyotrophic Lateral Sclerosis (ALS) Market: Geographical Analysis
7. Global Amyotrophic Lateral Sclerosis (ALS) Market Overview
7.1. Market Size & Forecast, 2019–2030
7.1.1. By Value (USD Billion)
7.2. Market Share and Forecast
7.2.1. By Type
7.2.1.1. Sporadic ALS (SALS)
7.2.1.2. Familial ALS (FALS)
7.2.2. By Treatment
7.2.2.1. Medication
7.2.2.2. Physical Therapy
7.2.2.3. Respiratory Therapy
7.2.2.4. Speech Therapy
7.2.2.5. Others
7.2.3. By End User
7.2.3.1. Specialty Centers
7.2.3.2. Research & Academic Institutes
7.2.3.3. Others
7.2.4. By Region
7.2.4.1. North America
7.2.4.2. Europe
7.2.4.3. Asia Pacific (APAC)
7.2.4.4. Latin America (LATAM)
7.2.4.5. Middle East and Africa (MEA)
8. North America Amyotrophic Lateral Sclerosis (ALS) Market
8.1. Market Size & Forecast, 2019–2030
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment
8.2.3. By End User
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. By Type
8.2.4.1.2. By Treatment
8.2.4.1.3. By End User
8.2.4.2. Canada
8.2.4.2.1. By Type
8.2.4.2.2. By Treatment
8.2.4.2.3. By End User
9. Europe Amyotrophic Lateral Sclerosis (ALS) Market
9.1. Market Size & Forecast, 2019–2030
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment
9.2.3. By End User
9.2.4. By Country
9.2.4.1. Germany
9.2.4.1.1. By Type
9.2.4.1.2. By Treatment
9.2.4.1.3. By End User
9.2.4.2. United Kingdom
9.2.4.2.1. By Type
9.2.4.2.2. By Treatment
9.2.4.2.3. By End User
9.2.4.3. Italy
9.2.4.3.1. By Type
9.2.4.3.2. By Treatment
9.2.4.3.3. By End User
9.2.4.4. France
9.2.4.4.1. By Type
9.2.4.4.2. By Treatment
9.2.4.4.3. By End User
9.2.4.5. Spain
9.2.4.5.1. By Type
9.2.4.5.2. By Treatment
9.2.4.5.3. By End User
9.2.4.6. Belgium
9.2.4.6.1. By Type
9.2.4.6.2. By Treatment
9.2.4.6.3. By End User
9.2.4.7. Russia
9.2.4.7.1. By Type
9.2.4.7.2. By Treatment
9.2.4.7.3. By End User
9.2.4.8. The Netherlands
9.2.4.8.1. By Type
9.2.4.8.2. By Treatment
9.2.4.8.3. By End User
9.2.4.9. Rest of Europe
9.2.4.9.1. By Type
9.2.4.9.2. By Treatment
9.2.4.9.3. By End User
10. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market
10.1. Market Size & Forecast, 2019–2030
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Treatment
10.2.3. By End User
10.2.4. By Country
10.2.4.1. China
10.2.4.1.1. By Type
10.2.4.1.2. By Treatment
10.2.4.1.3. By End User
10.2.4.2. India
10.2.4.2.1. By Type
10.2.4.2.2. By Treatment
10.2.4.2.3. By End User
10.2.4.3. Japan
10.2.4.3.1. By Type
10.2.4.3.2. By Treatment
10.2.4.3.3. By End User
10.2.4.4. South Korea
10.2.4.4.1. By Type
10.2.4.4.2. By Treatment
10.2.4.4.3. By End User
10.2.4.5. Australia & New Zealand
10.2.4.5.1. By Type
10.2.4.5.2. By Treatment
10.2.4.5.3. By End User
10.2.4.6. Indonesia
10.2.4.6.1. By Type
10.2.4.6.2. By Treatment
10.2.4.6.3. By End User
10.2.4.7. Malaysia
10.2.4.7.1. By Type
10.2.4.7.2. By Treatment
10.2.4.7.3. By End User
10.2.4.8. Singapore
10.2.4.8.1. By Type
10.2.4.8.2. By Treatment
10.2.4.8.3. By End User
10.2.4.9. Vietnam
10.2.4.9.1. By Type
10.2.4.9.2. By Treatment
10.2.4.9.3. By End User
10.2.4.10. Rest of APAC
10.2.4.10.1. By Type
10.2.4.10.2. By Treatment
10.2.4.10.3. By End User
11. Latin America Amyotrophic Lateral Sclerosis (ALS) Market
11.1. Market Size & Forecast, 2019–2030
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Treatment
11.2.3. By End User
11.2.4. By Country
11.2.4.1. Brazil
11.2.4.1.1. By Type
11.2.4.1.2. By Treatment
11.2.4.1.3. By End User
11.2.4.2. Mexico
11.2.4.2.1. By Type
11.2.4.2.2. By Treatment
11.2.4.2.3. By End User
11.2.4.3. Argentina
11.2.4.3.1. By Type
11.2.4.3.2. By Treatment
11.2.4.3.3. By End User
11.2.4.4. Peru
11.2.4.4.1. By Type
11.2.4.4.2. By Treatment
11.2.4.4.3. By End User
11.2.4.5. Rest of LATAM
11.2.4.5.1. By Type
11.2.4.5.2. By Treatment
11.2.4.5.3. By End User
12. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market
12.1. Market Size & Forecast, 2019–2030
12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By Treatment
12.2.3. By End User
12.2.4. By Country
12.2.4.1. Saudi Arabia
12.2.4.1.1. By Type
12.2.4.1.2. By Treatment
12.2.4.1.3. By End User
12.2.4.2. UAE
12.2.4.2.1. By Type
12.2.4.2.2. By Treatment
12.2.4.2.3. By End User
12.2.4.3. Qatar
12.2.4.3.1. By Type
12.2.4.3.2. By Treatment
12.2.4.3.3. By End User
12.2.4.4. Kuwait
12.2.4.4.1. By Type
12.2.4.4.2. By Treatment
12.2.4.4.3. By End User
12.2.4.5. South Africa
12.2.4.5.1. By Type
12.2.4.5.2. By Treatment
12.2.4.5.3. By End User
12.2.4.6. Nigeria
12.2.4.6.1. By Type
12.2.4.6.2. By Treatment
12.2.4.6.3. By End User
12.2.4.7. Algeria
12.2.4.7.1. By Type
12.2.4.7.2. By Treatment
12.2.4.7.3. By End User
12.2.4.8. Rest of MEA
12.2.4.8.1. By Type
12.2.4.8.2. By Treatment
12.2.4.8.3. By End User
13. Competitive Landscape
13.1. List of Key Players and Their Offerings
13.2. Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis, 2023
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
14. Impact of Escalating Geopolitical Tensions on Global Amyotrophic Lateral Sclerosis (ALS) Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
15.1. Mitsubishi Tanabe Pharma Corporation
15.2. Otsuka Pharmaceutical Co., Ltd
15.3. BrainStorm Therapeutics
15.4. Biogen Inc.
15.5. Corestem
15.6. AB Science
15.7. F.Hoffmann-La Roche AG
15.8. Biohaven Pharmaceutical
15.9. Sun Pharmaceutical
15.10. Ionis Pharmaceuticals, Inc.
15.11. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
17.1. Qualitative Research
17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
17.3.1. Secondary Research
17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us